Dr. Voorhees on Treatments for Patients With Relapsed Multiple Myeloma

Peter Voorhees, MD
Published: Friday, Apr 27, 2018



Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

There are a lot of available options for patients with relapsed multiple myeloma, states Voorhees. At this point, triplet therapies have outperformed doublets in the frontline setting. An example of this would be the lenalidomide (Revlimid) dexamethasone triplets.

The other thing that is important to recognize, says Voorhees, is that avoiding toxicity in frail patients. The monoclonal antibodies elotuzumab (Empliciti) and daratumumab (Darzalex) are easily added to backbone doublets of lenalidomide and dexamethasone. These frail patients, who physicians would traditionally reserve doublets for, may be good candidates for triplets in specific scenarios.
 
SELECTED
LANGUAGE


Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.

There are a lot of available options for patients with relapsed multiple myeloma, states Voorhees. At this point, triplet therapies have outperformed doublets in the frontline setting. An example of this would be the lenalidomide (Revlimid) dexamethasone triplets.

The other thing that is important to recognize, says Voorhees, is that avoiding toxicity in frail patients. The monoclonal antibodies elotuzumab (Empliciti) and daratumumab (Darzalex) are easily added to backbone doublets of lenalidomide and dexamethasone. These frail patients, who physicians would traditionally reserve doublets for, may be good candidates for triplets in specific scenarios.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x